RS BioTherapeutics
[Closed for Investment] RS BioTherapeutics, with a valuation of $40 million, is raising funds on StartEngine. The company is bringing innovation in respiratory drug development to address inflammatory lung diseases. RS BioTherapeutics is initially focused on COPD and IPF with its innovative inhaled therapy, RSBT-001, and is opening new avenues for treatment and care. RSBT-001 is a multi-targeted immune modulator derived from cannabinoids and does not carry the side effects of using corticosteroids for targeting lung inflammation. Dean Hart founded RS BioTherapeutics in February 2021. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1.24 million. The campaign proceeds will be used for product development, safety and toxicology study design, and operations.
Investment Overview
Raised: $196,189
Deal Terms
Total Commitments ($USD)
- Platform
- StartEngine
- Start Date
- 04/30/2024
- Close Date
- 07/29/2024
$10,000
$1,235,000
$500
Convertible Note
Seed
RegCF
$40,000,000
15%
Company & Team
Company
- Year Founded
- 2021
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $5,522,307
- VC Backed?
- No
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 07/29/2024 | StartEngine | $40,000,000 | $196,189 | Convertible Note | Funded | RegCF |